Outcome | N trials/N pooled | WMF (M) | RR (95% CI) | I2 | SOE* | N trials/N pooled | WMF (M) | RR (95% CI) | I2 |
---|---|---|---|---|---|---|---|---|---|
 | All eligible trials | Limited to good quality trials | |||||||
Catheter Aspiration | Â | Â | Â | Â | Â | Â | Â | Â | Â |
   Mortality | 11/10 | 7.92 | 0.69 (0.47 to 1.02) | 0% | Low | 10/10 | 8.08 | 0.70 (0.47 to 1.03) | 0% |
Myocardial infarction | 10/10 | 8.80 | 0.61 (0.36 to 1.04) | 0% | Low | 10/10 | 8.80 | 0.61 (0.36 to 1.04) | 0% |
   Stroke | 5/4 | 0.79 | 3.18 (0.73 to 13.88) | 0% | Insufficient | 5/4 | 0.79 | 3.18 (0.73 to 13.88) | 0% |
Target revascularization | 9/9 | 9.48 | 0.79 (0.61 to 1.02) | 0% | Low | 9/9 | 9.48 | 0.79 (0.61 to 1.02) | 0% |
   MACE | 11/11 | 12.43 | 0.73 (0.61 to 0.88) | 0% | High | 11/11 | 12.43 | 0.73 (0.61 to 0.88) | 0% |
   HRQoL | 0 | --- | --- | --- | Insufficient | 0 | --- | --- | --- |
Mechanical Thrombectomy | Â | Â | Â | Â | Â | Â | Â | Â | Â |
   Mortality | 5/4 | 7.80 | 1.19 (0.51 to 2.76) | 54.9 | Insufficient | 5/4 | 7.80 | 1.19 (0.51 to 2.76) | 54.9 |
Myocardial infarction | 5/3 | 8.98 | 0.71 (0.27 to 1.85) | 0% | Insufficient | 5/3 | 8.98 | 0.71 (0.27 to 1.85) | 0% |
   Stroke | 5/4 | 5.79 | 2.42 (0.75 to 7.78) | 0% | Insufficient | 5/4 | 5.79 | 2.42 (0.75 to 7.78) | 0% |
Target revascularization | 5/3 | 6.22 | 0.87 (0.36 to 2.10) | 39.2% | Insufficient | 5/3 | 6.22 | 0.87 (0.36 to 2.10) | 39.2% |
   MACE | 4/3 | 6.22 | 1.23 (0.50 to 3.01) | 79.9% | Insufficient | 4/3 | 6.22 | 1.23 (0.50 to 3.01) | 79.9% |
   HRQoL | 0 | --- | --- | --- | Insufficient | 0 | --- | --- | --- |
Distal Filter Embolic Protection | Â | Â | Â | Â | Â | Â | Â | Â | Â |
   Mortality | 5/5 | 10.84 | 0.97 (0.54 to 1.75) | 0% | Insufficient | 4/4 | 11.49 | 0.97 (0.53 to 1.79) | 0% |
Myocardial infarction | 5/4 | 11.22 | 0.72 (0.15 to 3.34) | 39.8% | Insufficient | 4/3 | 11.93 | 0.56 (0.06 to 5.02) | 60% |
   Stroke | 1/0 | 1 | 1.51 (0.30 to 7.52)†| NA | Insufficient | 1/0 | 1 | 1.51 (0.30 to 7.52)†| NA |
Target revascularization | 3/2 | 13.36 | 1.61 (1.03 to 2.54) | NA | Low | 3/2 | 13.36 | 1.61 (1.03 to 2.54) | NA |
   MACE | 5/5 | 10.84 | 1.34 (0.97 to 1.86) | 0% | Moderate | 4/4 | 11.49 | 1.36 (0.98 to 1.89) | 0% |
   HRQoL | 0 | --- | --- | --- | Insufficient | 0 | --- | --- | --- |
Distal Balloon Embolic Protection | Â | Â | Â | Â | Â | Â | Â | ||
   Mortality | 4/4 | 6 | 0.82 (0.45 to 1.51) | 2.5% | Insufficient | 4/4 | 6 | 0.82 (0.45 to 1.51) | 2.5% |
Myocardial infarction | 5/5 | 6 | 0.67 (0.29 to 1.57) | 0% | Insufficient | 5/5 | 6 | 0.67 (0.29 to 1.57) | 0% |
   Stroke | 1 | 6 | 0.48 (0.10 to 2.22)†| NA | Insufficient | 1/0 | 6 | 0.48 (0.10 to 2.22)†| NA |
Target revascularization | 5/5 | 6 | 0.93 (0.61 to 1.42) | 0% | Insufficient | 5/5 | 6 | 0.93 (0.61 to 1.42) | 0% |
   MACE | 6/5 | 6 | 0.87 (0.64 to 1.19) | 0% | Insufficient | 6/5 | 6 | 0.87 (0.64 to 1.19) | 0% |
   HRQoL | 0 | --- | --- | --- | Insufficient | 0 | --- | --- | --- |
Proximal Balloon Embolic Protection | Â | Â | Â | Â | Â | Â | Â | ||
   Mortality | 1/0 | 6 | 0.51 (0.11 to 2.33)†| NA | Insufficient | 1/0 | 6 | 0.51 (0.11 to 2.33)†| NA |
Myocardial infarction | 1/0 | 6 | 1.01 (0.24 to 4.33)†| NA | Insufficient | 1/0 | 6 | 1.01 (0.24 to 4.33)†| NA |
   Stroke | 1/0 | 6 | 0.20 (0 to 1.93)†| NA | Insufficient | 1/0 | 6 | 0.20 (0 to 1.93)†| NA |
Target revascularization | 1/0 | 6 | 0.71 (0.29 to 1.75)†| NA | Insufficient | 1/0 | 6 | 0.71 (0.29 to 1.75)†| NA |
   MACE | 1/0 | 6 | 0.74 (0.36 to 1.54)†| NA | Insufficient | 1/0 | 6 | 0.74 (0.36 to 1.54)†| NA |
   HRQoL | 0 | --- | --- | --- | Insufficient | 0 | --- | --- | --- |
Embolic Protection Devices | Â | Â | Â | Â | Â | Â | Â | Â | Â |
   Mortality | 10/10 | 8.11 | 0.87 (0.58 to 1.30) | 0% | Insufficient | 9/9 | 8.31 | 0.87 (0.57 to 1.31) | 0% |
Myocardial infarction | 11/10 | 8.08 | 0.83 (0.45 to 1.53) | 0% | Insufficient | 10/9 | 8.27 | 0.83 (0.45 to 1.55) | 0% |
   Stroke | 3/3 | 3.74 | 0.68 (0.22 to 2.11) | 0% | Insufficient | 3/3 | 3.74 | 0.68 (0.22 to 2.11) | 0% |
Target revascularization | 9/8 | 8.60 | 1.11 (0.80 to 1.52) | 10% | Insufficient | 9/8 | 8.60 | 1.11 (0.80 to 1.52) | 10% |
   MACE | 12/11 | 7.97 | 1.04 (0.84 to 1.29) | 0% | Moderate | 11/10 | 8.15 | 1.03 (0.82 to 1.29) | 4% |
   HRQoL | 0 | --- | --- | --- | Insufficient | 0 | --- | --- | --- |